ArticleBritish journal of haematology2022
Checkpoint CD47 expression in classical Hodgkin lymphoma.
Article in British journal of haematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Survival and Clinicopathological Significance of CD47 in Human Solid Tumors: An Updated Systematic Reviews and Meta-Analysis.Cancer reports (Hoboken, N.J.) · 2025Pooled it
- CD47 Expression in Classic Hodgkin Lymphoma and Its Association With Tumor Microenvironment.Journal of immunology research · 2026Article
- CircRNA-mediated regulation of immune checkpoints in lymphoma: a multidimensional network perspective.Frontiers in immunology · 2026Review
- Dissecting CD47 expression in lymphoid neoplasms to inform precision immunotherapy with anti-CD47 phagocytic checkpoint blockade.Haematologica · 2025Article
- Targeting myeloid cells for hematological malignancies: the present and future.Biomarker research · 2025Review
- Does CD47 expression have prognostic significance in classical Hodgkin lymphoma?Turkish journal of medical sciences · 2025Article
- Letter to the editor regarding "Kılıçarslan A, Kurt Çevik G, Doğan M, Aksoy Altınboğa A, Ceran F, et al. Does CD47 expression have prognostic significance in classical Hodgkin lymphoma? Turkish Journal of Medical Sciences: 2025; 55 (1): 22".Turkish journal of medical sciences · 2025Article
- Article
- Effects of a humanized CD47 antibody and recombinant SIRPα proteins on triple negative breast carcinoma stem cells.Frontiers in cell and developmental biology · 2024Article
- Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy.Cancers · 2023Review
- Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications.Biology · 2023Review
- Targeting macrophages in hematological malignancies: recent advances and future directions.Journal of hematology & oncology · 2022Review
- Checkpoint CD47 expression in classical Hodgkin lymphoma.British journal of haematology · 2022Article
- Current and Emerging Approaches to Study Microenvironmental Interactions and Drug Activity in Classical Hodgkin Lymphoma.Cancers · 2022Review
- Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The glycoprotein CD47 regulates antiphagocytic activity via signal regulatory protein alpha (SIRPa). This study investigated CD47 expression on Hodgkin and Reed-Sternberg (HRS) cells in the classical Hodgkin lymphoma (cHL) tumour microenvironment and its correlation with prognosis, programmed-death (PD) immune markers, and SIRPa
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.